Patients in Wales, U.K. can now be added to the growing list of people affected by gadolinium related illness. Some Welsh residents have come forward to voice their complaints about symptoms of debilitating pain, chronic fatigue and involuntary muscle spasms after receiving an MRI using gadolinium-based contrast agents.

These affected patients are calling for their government to include more information on consent forms as they do not feel that they were adequately informed prior to having their MRI. The U.S. has already implemented this change based on the results of recent studies showing that gadolinium is retained in the brain and body tissues longer than was previously believed.

The Medicines and Healthcare products Regulatory Agency (MHRA) in Wales issued a statement that “GdCAs [gadolinium contrast agents] should be used only when diagnostic information is essential and cannot be obtained with an MRI scan alone, and should be used at the lowest effective dose. When used in this way their benefits outweigh their risks in patients without kidney complaints”.

A Welsh pediatrician reported that she had such debilitating symptoms after receiving gadolinium, she was forced to leave her position. She stated that GdCAs should not have been granted licenses without further research.

Read more about these patient reports at: https://www.walesonline.co.uk/news/health/patients-claim-experiencing-pain-fatigue-15579228

Please join the growing list of advocates and sign our petition so we can help promote the development of safer alternatives and effective treatments to remove gadolinium from patients affected by it.